This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Amgen Names Steven K. Galson, Senior Vice President, Global Regulatory Affairs And Safety

Stocks in this article: AMGN





THOUSAND OAKS, Calif., May 12, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Steven K. Galson, M.D., M.P.H., to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. Galson will report to Sean E. Harper, M.D., executive vice president, Research and Development, and will be responsible for all regulatory and patient safety functions across Amgen.

Galson joined Amgen as vice president of Global Regulatory Affairs in October 2010. "Steven has led Amgen's regulatory team for the past three and a half years, and his success in this critical role has prepared him for these expanded responsibilities," said Harper. "Steven's deep and broad experience in both the public and private health sectors makes him an excellent choice to manage the unprecedented number of regulatory filings that Amgen has planned, and to lead our effort to continually evaluate and communicate the safety profile of our medicines."

Galson came to Amgen from Science Applications International Corporation, where he served as senior vice president for Civilian Health Operations and chief health scientist from October 2009 through October 2010.

Prior to that, Galson had a distinguished 23-year career in United States (U.S.) Public Health Service. From 2007 to 2009, he was acting U.S. Surgeon General. During the Bush-Obama transition in 2009, he was the acting Assistant Secretary for Health. From 2001 to 2007, he served as deputy director and director of the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, where he provided leadership for the center's broad national and international programs in pharmaceutical regulation.

Prior to his arrival at the FDA, Galson was director of the Environmental Protection Agency's Office of Science Coordination and Policy, Office of Prevention, Pesticides and Toxic Substances. He has also served as the Chief Medical Officer of the U.S. Department of Energy. He began his Public Health Service career as an epidemiological investigator at the Centers for Disease Control after completing a residency in internal medicine at the hospitals of the Medical College of Pennsylvania.

Galson is the recipient of numerous awards, including the Surgeon General's Medallion and the Secretary of Energy Gold Award. He has been a member of the National Board of Medical Examiners and a peer reviewer for medical journals. He is the co-chair of the Institute of Medicine Forum on Drug Discovery, Development and Translation and a member of the Board of Directors of Vanda Pharmaceuticals. He holds a Bachelor of Science from Stony Brook University, an M.D. from Mt. Sinai School of Medicine, an M.P.H. from the Harvard School of Public Health and an Honorary Doctor of Public Service from Drexel University. He is board certified in preventive medicine and public health and occupational medicine.

About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world, and is developing a pipeline of medicines with breakaway potential.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs